Acadia Phase 2 RADIANT: remlifanserin 60mg misses primary endpoint (p=0.0603) but supports Phase 3

ACADIA PHARMACEUTICALS INC

Primary SAPS-H+D: 60mg change -12.6 vs placebo -10.4 (week 6), effect size 0.26, p=0.0603.
Key secondary CGI-S-ADP: 60mg change -1.3 vs -0.9, effect size 0.37, p=0.0077 (nominal).
30mg dose minimal improvement; company to amend Phase 3 to remove 30mg arm.
Safety favorable: no QT signal, no deaths, no motor/cognition negative impact; AE rates similar to placebo.
Plan to continue Phase 3; detailed results at CTAD Nov 16-19, 2026 in Boston.

Featured in Daily 8-K Digest

Selected #8 for 2026-09-24. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.